U-M Therapeutics Licensing

Maximizing the positive societal impact of  U-M biopharma research discoveries.

U-M has a rich history of discovering compounds that lead to FDA approved treatments. An analysis by “Drug Discovery Today” found that U-M is the largest single contributor among academic institutions in creating FDA approved new molecular entities. U-M relies on partners to advance the early-stage discoveries from U-M labs through pre-clinical and clinical studies to achieve regulatory approval so that these new treatments can improve, extend and even save lives.

As an early adopter of AUTM’s Nine Points of Licensing in the Public Interest, U-M prioritizes  responsible stewardship of intellectual property to drive innovation and maximize public benefit. Our therapeutic licensing approach balances the significant investment required to develop early-stage discoveries with the need for diligent development and broad accessibility, ensuring that new treatments reach patients and create meaningful societal impact.

Learn more about Innovation Partnerships’ licensing process here.